
Ultra-Long-Acting IL-5 Inhibition: A Paradigm Shift in Asthma Care
Moving from monthly to twice-yearly dosing proved more consequential than expected, enabling directly observed therapy, continuity of care, and closer monitoring of each patient's response.
Episodes in this series

"Ultra-Long-Acting IL-5 Inhibition: A Paradigm Shift in Asthma Care" explores how an ultra-long-acting option is changing expectations for patients and providers alike.
Dr. Bernstein asks Dr. Mosnaim where she sees the most meaningful differentiation as the IL-5 class evolves. She says she is very excited about the ultra-long-acting anti-IL-5 therapy, depemokimab. Patients no longer need to manage at-home self-injection or coordinate with specialty pharmacy. They also do not need to think about their treatment for 6 months.
In her office, the drug is ordered in advance and given by staff who are proficient with injections. During the same visit, she reviews fractional exhaled nitric oxide, spirometry, and the Asthma Control Test. She also asks about exacerbations and symptoms.
She uses that visit to reinforce progress, reminding a patient of several exacerbations last year but none in the past 6 months. She can point to improved spirometry and control scores as tangible evidence.
She also highlights comorbidities as an important consideration with IL-5 therapies. Dr. Bernstein asks about nasal polyps. Dr. Mosnaim confirms that coexisting severe asthma and nasal polyps is one of the drivers of persistence on a biologic.
Dr. Bernstein then asks Dr. Chupp what is driving interest in extended-interval IL-5 treatment. Dr. Chupp calls the ultra-long-acting option a paradigm shift. It benefits providers through directly observed therapy and in-office monitoring, which confirm adherence. It benefits patients through far less frequent dosing.
He adds that it is potentially cost-saving, since less drug is given over time. Dosing every few weeks or months already seemed a major advance over daily inhalers. It was not obvious that moving from monthly to every 6 months would matter, but he says it is proving significant.
Patients are receptive, he says, because they already visit twice yearly. Dr. Bernstein notes that it assures continuity of care. Dr. Chupp agrees, identifying no-shows as the main risk, though he has not yet encountered that problem.
Up next, in "Selecting Asthma Patients for 6-Month IL-5 Dosing: Fit and Safety," Dr. Wechsler describes how he identifies the right candidates for twice-yearly dosing, and Dr. Mosnaim reviews the safety data from clinical trials.
Related to this article







